GGrantIndex
← Leaderboards

Philip O. Livingston

Sloan-Kettering Institute For Cancer Res

Google Scholar ↗PubMed ↗ORCID ↗
$8,464,484
Attributed
$10,784,539
Total exposure
12
Grants
9
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $1.4M · FY2005–18
$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18

Funding mix

By agency

NIH$10,784,539 · 12

By mechanism

P01$4,018,710 · 4
R01$2,603,717 · 1
R44$1,499,999 · 1
P50$1,352,705 · 1
R42$535,666 · 1
R41$399,590 · 2

Top collaborators

Most similar at Sloan-Kettering Institute For Cancer Res

Same institution · by research overlap

Others in their field

Top investigators on “Vaccines”

Research focus

VaccinesAntigensAntibody FormationVaccinationImmunologic AdjuvantsMalignant NeoplasmsResponseImmunogenicityDesignAntibodiesImmunizationAdjuvantClinical ResearchProgramsPeptidesPre-ClinicalVaccine DevelopmentKeyhole Limpet HemocyaninSaponinsCancer VaccinesTumor AntigensPreparationMelanomaGangliosides

Grant awards (28)

Large Scale Synthesis of the Next Generation Synthetic Saponin Adjuvant TiterQuil$743,432
R44 · FY2018 · AI · contact PI
Large Scale Synthesis of the Next Generation Synthetic Saponin Adjuvant TiterQuil$756,567
R44 · FY2017 · AI · contact PI
Large Scale Synthesis of the Next Generation Synthetic Saponin Adjuvant TiterQuil$225,000
R43 · FY2014 · AI · contact PI
Novel Adjuvant Discovery in Vaccine Therapy$871,728
R01 · FY2012 · AI
CONSTRUCTION AND TESTING OF A TRIVALENT VACCINE AGAINST NEUROBLASTOMA ADMINISTERE$149,152
R43 · FY2012 · CA · contact PI
Novel Adjuvant Discovery in Vaccine Therapy$869,286
R01 · FY2011 · AI
Novel Adjuvant Discovery in Vaccine Therapy$862,703
R01 · FY2010 · AI
Characterization of human antibodies to sialyl-Lewis A (sLeA) derived from patien$535,666
R42 · FY2010 · CA · contact PI
Development of Antibody and T-Cell Inducing Vaccines$659,761
P01 · FY2009 · CA · contact PI
Regulation by the Immune Response to Vaccines by Botanicals$293,521
P50 · FY2009 · AT · contact PI
Immune Monitoring$234,123
P01 · FY2009 · CA · contact PI
Development of Antibody and T-Cell Inducing Vaccines$642,726
P01 · FY2008 · CA · contact PI
Human Monoclonal Antibodies from Immunized Patient Lymphocytes$197,764
R41 · FY2008 · CA · contact PI
Regulation by the Immune Response to Vaccines by Botanicals$157,700
P50 · FY2008 · AT · contact PI
Immune Monitoring$125,000
P01 · FY2008 · CA · contact PI
Development of Antibody and T-Cell Inducing Vaccines$638,623
P01 · FY2007 · CA · contact PI
Regulation by the Immune Response to Vaccines by Botanicals$307,086
P50 · FY2007 · AT · contact PI
Pilot trial with a tetravalent conjugate vaccine against small cell lung cancer$201,826
R41 · FY2007 · CA · contact PI
Regulation by Immune Response to Vaccine by Botanicals$301,456
P50 · FY2006 · AT · contact PI
Development of Antibody and T-Cell Inducing Vaccines$291,812
P01 · FY2006 · CA · contact PI
Regulation by Immune Response to Vaccine by Botanicals$292,942
P50 · FY2005 · AT
Development of Antibody and T-Cell Inducing Vaccines$283,491
P01 · FY2005 · CA
GLYCOLIPID AND PROTEIN VACCINES AGAINST CANCER$291,807
P01 · FY2002 · CA
CLINICAL TRIALS WITH ACTIVE AND PASSIVE IMMUNOTHERAPY AGAINST OVARIAN CANCER$0
P01 · FY2002 · CA
GLYCOLIPID AND PROTEIN VACCINES AGAINST CANCER$291,807
P01 · FY2001 · CA
CLINICAL TRIALS WITH ACTIVE AND PASSIVE IMMUNOTHERAPY AGAINST OVARIAN CANCER$0
P01 · FY2001 · CA
GLYCOLIPID AND PROTEIN VACCINES AGAINST CANCER$291,807
P01 · FY2000 · CA
CLINICAL TRIALS WITH ACTIVE AND PASSIVE IMMUNOTHERAPY AGAINST OVARIAN CANCER$267,753
P01 · FY2000 · CA